Top

Published in:

01-04-2018 | Topic Review

Localized targeted antiangiogenic drug delivery for glioblastoma

Authors: Gregory D. Arnone, Abhiraj D. Bhimani, Tania Aguilar, Ankit I. Mehta

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Systemic delivery of antiangiogenic agents has been ineffective in improving the overall survival of patients with both primary and recurrent glioblastoma, in part due to dose-limiting toxicities. With the development of new and efficient localized delivery methods and vehicles, an otherwise lethal dose of antiangiogenic chemotherapy can be used to treat tumors while minimizing systemic side effects. Current in-vitro and in-vivo animal studies have shown promising results that encourage the pursuit towards human clinical trials for localized antiangiogenic treatment in the near future.

Ung TH, Malone H, Canoll P, Bruce JN (2015) Convection-enhanced delivery for glioblastoma: targeted delivery of antitumor therapeutics. CNS Oncol 4:225–234. https://doi.org/10.2217/cns.15.12 CrossRefPubMedPubMedCentral

Roy S, Lahiri D, Maji T, Biswas J (2015) Recurrent glioblastoma: where we stand. South Asian J Cancer 4:163–173. https://doi.org/10.4103/2278-330X.175953 CrossRefPubMedPubMedCentral

Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS (2011) A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 9:414–427CrossRefPubMedPubMedCentral

Wicks RT, Azadi J, Mangraviti A, Zhang I, Hwang L, Joshi A, Bow H, Hutt-Cabezas M, Martin KL, Rudek MA, Zhao M, Brem H, Tyler BM (2015) Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. Neuro Oncol 17:70–80. https://doi.org/10.1093/neuonc/nou143 CrossRefPubMed

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507. https://doi.org/10.1056/NEJMra0708126 CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996 https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202. https://doi.org/10.1016/j.ejca.2012.04.011 CrossRefPubMed

Soda Y, Myskiw C, Rommel A, Verma IM (2013) Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) 91:439–448. https://doi.org/10.1007/s00109-013-1019-z CrossRef

Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500–1502CrossRefPubMed

10.

Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259. https://doi.org/10.1158/1078-0432.CCR-06-2309 CrossRefPubMed

11.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745. https://doi.org/10.1200/JCO.2008.16.3055 CrossRefPubMed

12.

Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92:149–155. https://doi.org/10.1007/s11060-008-9745-8 CrossRefPubMed

13.

Xu T, Chen J, Lu Y, Wolff JE (2010) Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 10:252. https://doi.org/10.1186/1471-2407-10-252 CrossRefPubMedPubMedCentral

14.

Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6:465–477. https://doi.org/10.1038/nrclinonc.2009.94 CrossRefPubMed

15.

Zhou J, Atsina K-B, Himes BT, Strohbehn GW, Saltzman WM (2012) Novel delivery strategies for glioblastoma. Cancer J. https://doi.org/10.1097/PPO.0b013e318244d8ae CrossRefPubMedPubMedCentral

16.

Bhujbal SV, de Vos P, Niclou SP (2014) Drug and cell encapsulation: alternative delivery options for the treatment of malignant brain tumors. Adv Drug Deliv Rev 67–68:142–153. https://doi.org/10.1016/j.addr.2014.01.010 CrossRefPubMed

17.

Wolinsky JB, Colson YL, Grinstaff MW (2012) Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 159:14–26CrossRefPubMed

18.

Garrastazu Pereira G, Lawson AJ, Buttini F, Sonvico F (2016) Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Deliv 23:2881–2896. https://doi.org/10.3109/10717544.2015.1114047 CrossRefPubMed

19.

Perry J, Chambers A, Spithoff K, Laperriere N (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 14:189–194CrossRefPubMedPubMedCentral

20.

Storm PB, Renard VM, Moriarity JL, Tyler B, Wilentz RE, Brem H, Weingart JD (2004) Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. Cancer Chemother Pharmacol 54:361–367CrossRefPubMed

21.

Vilar G, Tulla-Puche J, Albericio F (2012) Polymers and drug delivery systems. Curr Drug Deliv 9:367–394CrossRefPubMed

22.

Benny O, Duvshani-Eshet M, Cargioli T, Bello L, Bikfalvi A, Carroll RS, Machluf M (2005) Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth. Clin Cancer Res 11:768–776PubMed

23.

Shivinsky A, Bronshtein T, Haber T, Machluf M (2015) The effect of AZD2171-or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model. Biomed Microdevices 17:1–15CrossRef

24.

Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, Aghi MK (2017) Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg 126:191–200. https://doi.org/10.3171/2016.1.JNS151591 CrossRefPubMed

25.

Watanabe M, Boyer JL, Crystal RG (2010) AAVrh. 10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Therapy 17:1042–1051CrossRefPubMedPubMedCentral

26.

Ding I, Sun JZ, Fenton B, Liu WM, Kimsely P, Okunieff P, Min W (2001) Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res 61:526–531PubMed

27.

Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H (2014) Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 4:126. https://doi.org/10.3389/fonc.2014.00126 CrossRefPubMedPubMedCentral

28.

Liu HL, Fan CH, Ting CY, Yeh CK (2014) Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. Theranostics 4:432–444. https://doi.org/10.7150/thno.8074 CrossRefPubMedPubMedCentral

29.

Ai X, Zhong L, Niu H, He Z (2014) Thin-film hydration preparation method and stability test of DOX-loaded disulfide-linked polyethylene glycol 5000-lysine-di-tocopherol succinate nanomicelles. Asian J Pharm Sci 9:244–250CrossRef

30.

Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K (2007) Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121:901–907. https://doi.org/10.1002/ijc.22732 CrossRefPubMed

31.

Wei KC, Chu PC, Wang HY, Huang CY, Chen PY, Tsai HC, Lu YJ, Lee PY, Tseng IC, Feng LY, Hsu PW, Yen TC, Liu HL (2013) Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. PLoS ONE 8:e58995. https://doi.org/10.1371/journal.pone.0058995 CrossRefPubMedPubMedCentral

32.

Liu HL, Hua MY, Chen PY, Chu PC, Pan CH, Yang HW, Huang CY, Wang JJ, Yen TC, Wei KC (2010) Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 255:415–425. https://doi.org/10.1148/radiol.10090699 CrossRefPubMed

33.

Aryal M, Vykhodtseva N, Zhang YZ, Park J, McDannold N (2013) Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model. J Control Release 169:103–111. https://doi.org/10.1016/j.jconrel.2013.04.007 CrossRefPubMedPubMedCentral

34.

Bize P, Duran R, Fuchs K, Dormond O, Namur J, Decosterd LA, Jordan O, Doelker E, Denys A (2016) Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. Radiology 280:425–435. https://doi.org/10.1148/radiol.2016150361 CrossRefPubMed

35.

Stefanadis C, Toutouzas K, Tsiamis E, Vavuranakis M, Stefanadi E, Kipshidze N (2008) First-in-man study with bevacizumab-eluting stent: a new approach for the inhibition of atheromatic plaque neovascularisation. EuroIntervention 3:460–464CrossRefPubMed

36.

Read T-A, Sorensen DR, Mahesparan R, Enger P, Timpl R, Olsen BR, Hjelstuen MH, Haraldseth O, Bjerkvig R (2001) Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 19:29–34CrossRefPubMed

37.

Cattaneo MG, Pola S, Francescato P, Chillemi F, Vicentini LM (2003) Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp Cell Res 283:230–236CrossRefPubMed

38.

Pradilla G, Legnani FG, Petrangolini G, Francescato P, Chillemi F, Tyler BM, Gaini SM, Brem H, Olivi A, DiMeco F (2005) Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. Neurosurgery 57:1032CrossRefPubMed

39.

Benny O, Menon LG, Ariel G, Goren E, Kim S-K, Stewman C, Black PM, Carroll RS, Machluf M (2009) Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth. Clin Cancer Res 15:1222–1231CrossRefPubMed

40.

Tamargo RJ, Leong KW, Brem H (1990) Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J Neuro Oncol 9:131–138CrossRef

41.

Schnoor R, Maas SL, Broekman ML (2015) Heparin in malignant glioma: review of preclinical studies and clinical results. J Neuro Oncol 124:151–156CrossRef

42.

Tamargo RJ, Bok RA, Brem H (1991) Angiogenesis inhibition by minocycline. Can Res 51:672–675

43.

Frazier JL, Wang PP, Case D, Tyler BM, Pradilla G, Weingart JD, Brem H (2003) Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. J Neuro Oncol 64:203–209CrossRef

44.

Bow H, Hwang LS, Schildhaus N, Xing J, Murray L, Salditch Q, Ye X, Zhang Y, Weingart J, Brem H (2014) Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma: laboratory investigation. J Neurosurg 120:662–669CrossRefPubMed

45.

Wang W, Sivakumar W, Torres S, Jhaveri N, Vaikari VP, Gong A, Howard A, Golden EB, Louie SG, Schönthal AH (2015) Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Neurosurg Focus 38:E8CrossRefPubMed

46.

Hicks MJ, Funato K, Wang L, Aronowitz E, Dyke JP, Ballon DJ, Havlicek DF, Frenk EZ, De BP, Chiuchiolo MJ (2015) Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Therapy 22:1–8CrossRefPubMed

47.

Fan C-H, Ting C-Y, Liu H-L, Huang C-Y, Hsieh H-Y, Yen T-C, Wei K-C, Yeh C-K (2013) Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment. Biomaterials 34:2142–2155CrossRefPubMed

48.

von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, Herms J, Winkler F (2011) Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 17:6192–6205. https://doi.org/10.1158/1078-0432.CCR-10-1868 CrossRef

49.

Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131–1138. https://doi.org/10.1634/theoncologist.2009-0121 CrossRefPubMed

50.

Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi J, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M, NPC-08 study group (2014) A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas. Neurol Med Chir (Tokyo) 54: 290–301CrossRef

51.

Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN (2000) Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47:1391–1398. (Discussion 1398–1399)CrossRefPubMed

Title: Localized targeted antiangiogenic drug delivery for glioblastoma
Authors: Gregory D. Arnone
Abhiraj D. Bhimani
Tania Aguilar
Ankit I. Mehta
Publication date: 01-04-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2747-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Localized targeted antiangiogenic drug delivery for glioblastoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis

Analysis of immunobiologic markers in primary and recurrent glioblastoma

PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity

Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system

Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma